Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons

被引:33
作者
Castilla, Jesus [1 ,2 ]
Navascues, Ana [3 ]
Fernandez-Alonso, Mirian [4 ]
Reina, Gabriel [4 ]
Pozo, Francisco [5 ]
Casado, Itziar [1 ,2 ]
Guevara, Marcela [1 ,2 ]
Martinez-Baz, Ivan [1 ,2 ]
Barricarte, Aurelio [1 ,2 ]
Ezpeleta, Carmen [3 ]
机构
[1] Inst Salud Publ Navarra, IdiSNA Navarra Inst Hlth Res, Pamplona 31003, Spain
[2] CIBERESP, Barcelona, Spain
[3] Complejo Hosp Navarra, IdiSNA Navarra Inst Hlth Res, Pamplona, Spain
[4] Univ Navarra Clin, IdiSNA Navarra Inst Hlth Res, Pamplona, Spain
[5] WHO Natl Influenza Ctr Madrid, Ctr Nacl Microbiol, Inst Salud Carlos III, Majadahonda, Spain
基金
欧盟地平线“2020”;
关键词
Influenza; Influenza vaccine; Split-virion vaccine; Subunit vaccine; Vaccine effectiveness; VIRUS INFECTION; CROSS-SEASON; PROTECTION; CHILDREN; VACCINES; REACTOGENICITY; A(H1N1)PDM09; CORRELATE; IMMUNITY; DISEASE;
D O I
10.1016/j.vaccine.2016.01.054
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In Navarra, Spain, subunit vaccine was first used in the 2014-2015 season, whereas trivalent split-virion influenza vaccines had been used in previous seasons. We estimate the effectiveness of the subunit vaccine in the current season and split vaccine in the two previous seasons against laboratory confirmed influenza in the 2014-2015 season. Methods: Patients with influenza-like illness hospitalized or attended by sentinel general practitioners were swabbed for influenza testing. The previous and current vaccine status of laboratory-confirmed cases was compared to test-negative controls. Results: Among 1213 patients tested, 619 (51%) were confirmed for influenza virus: 52% influenza A(H3N2), 46% influenza B, and 2% A(H1N1)pdm09. The overall effectiveness for subunit vaccination in the current season was 19% (95% confidence interval [CI]: -13 to 42), 2% (95%CI: -47 to 35) against influenza A(H3N2) and 32% (95%CI: -4 to 56) against influenza B. The effectiveness against any influenza was 67% (95%CI: 17-87) for 2012-2013 and 2013-2014 vaccination only, 42% (95%CI: -31 to 74) for 2014-2015 vaccination only, and 38% (95%CI: 8-58) for vaccination in the 2012-2013,2013-2014 and 2014-2015 seasons. The same estimates against influenza A(H3N2) were 47% (95%CI: -60 to 82), -54% (95%CI: -274 to 37) and 28% (95%CI: -17 to 56), and against influenza B were 82% (95%CI: 19-96), 93% (95%CI: 45-99) and 43% (95%CI: 5-66), respectively. Conclusion: These results suggest a considerable residual protection of split vaccination in previous seasons, low overall effectiveness of current season subunit vaccination, and possible interference between current subunit and previous split vaccines. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1350 / 1357
页数:8
相关论文
共 38 条
  • [1] Agencia Espanola de Medicamentos y Productos Sanitarios, CHIR RES CAR PROD
  • [2] Aguilar I, 2012, EUROSURVEILLANCE, V17, P20154
  • [3] [Anonymous], 2015, Wkly Epidemiol Rec, V90, P89
  • [4] [Anonymous], 2014, Wkly Epidemiol Rec, V89, P93
  • [5] [Anonymous], 2013, Wkly Epidemiol Rec, V88, P101
  • [6] Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines - A review and meta-analysis of the literature
    Beyer, WEP
    Palache, AM
    Osterhaus, ADME
    [J]. CLINICAL DRUG INVESTIGATION, 1998, 15 (01) : 1 - 12
  • [7] Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed Influenza
    Castilla, Jesus
    Godoy, Pere
    Dominguez, Angela
    Martinez-Baz, Ivan
    Astray, Jenaro
    Martin, Vicente
    Delgado-Rodriguez, Miguel
    Baricot, Maretva
    Soldevila, Nuria
    Maria Mayoral, Jose
    Maria Quintana, Jose
    Carlos Galan, Juan
    Castro, Ady
    Gonzalez-Candelas, Fernando
    Garin, Olatz
    Saez, Marc
    Tamames, Sonia
    Pumarola, Tomas
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 (02) : 167 - 175
  • [8] In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses
    Co, Mary Dawn T.
    Orphin, Laura
    Cruz, John
    Pazoles, Pamela
    Green, Karin M.
    Potts, James
    Leporati, Anita M.
    Babon, Jenny Aurielle B.
    Evans, James E.
    Ennis, Francis A.
    Terajima, Masanori
    [J]. VACCINE, 2009, 27 (02) : 319 - 327
  • [9] Epstein SL, 1998, J IMMUNOL, V160, P322
  • [10] European Centre for Disease Prevention and Control, 2015, INFL VIR CHAR SUMM E